Hayward, California headquartered Impax Laboratories Inc.'s stock finished Wednesday's session 1.05% lower at $14.15 with a total volume of 1.09 million shares traded. Shares of the Company, which develops, manufactures, and markets bioequivalent pharmaceutical products, are trading at a PE ratio of 30.24. The stock is trading below its 50-day and 200-day moving averages by 36.18% and 51.11%, respectively. Impax Laboratories' stock has a Relative Strength Index (RSI) of 23.83.
On November 9th, 2016, Impax Labs reported that total revenues in Q3 2016 increased 3% to $227.9 million compared to $221.1 million in the prior year's period. On a GAAP basis, the Company recorded a per share loss of $2.51 in Q3 2016 compared to a gain of $0.49 per share in the prior year's period. Adjusted diluted earnings per share for Q3 2016 were $0.37 compared to adjusted EPS of $0.40 in Q3 2015.
On November 14th, 2016, research firm WallachBeth downgraded the Company's stock rating from 'Buy' to 'Hold'. The research firm also revised downwards its previous target price from $30 to $18. Visit us today and access our complete research report on IPXL at:
On Wednesday, shares in California headquartered Retrophin Inc. ended the session 2.39% higher at $21.41 with a total volume of 708,090 shares traded. Retrophin's shares have gained 3.68% in the last one month, 25.72% in the previous three months, and 15.60% in the past one year. The stock is trading 0.23% above its 50-day moving average and 22.79% above its 200-day moving average. Moreover, shares of the Company have an RSI of 58.22.
On November 10th, 2016, Retrophin announced it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a Phase 3 clinical trial evaluating RE-024, the Company's novel investigational replacement therapy, for the treatment of pantothenate kinase-associated neurodegeneration (PKAN). The SPA indicates concurrence by the FDA that the design of the pivotal trial can adequately support a New Drug Application seeking U.S. approval of RE-024 for the treatment of PKAN. The Company plans to initiate this trial before year-end 2016. The complimentary report on RTRX can be downloaded at:
On Wednesday, shares in Redwood City, California headquartered Heron Therapeutics Inc. recorded a trading volume of 645,889 shares, which was higher than their three months average volume of 592,440 shares. The stock ended the day 3.44% lower at $19.65. Heron Therapeutics' stock has gained 27.60% in the last one month. The Company is trading above its 50-day and 200-day moving averages by 14.57% and 6.72%, respectively. Furthermore, shares of Heron Therapeutics, which develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the US, have an RSI of 66.10.
On October 26th, 2016, research firm Aegis Capital initiated a 'Buy' rating on the Company's stock.
On November 9th, 2016, Heron's net cash used for operating activities was $36.1 million for Q3 2016 compared to net cash used for operating activities of $19.9 million for Q3 2015. Heron's net loss for Q3 2016 was $48.5 million, or $1.24 per share, compared to a net loss of $22.7 million, or $0.63 per share, for Q3 2015. Register for free on Stock-Callers.com and access the latest research report on HRTX at:
Cambridge, the UK-based GW Pharmaceuticals PLC's stock declined 3.59%, to close the day at $129.21. The stock recorded a trading volume of 584,657 shares. GW Pharma's shares have gained 3.19% in the last one month, 53.53% in the previous three months, and 53.04% in the past one year. Shares of the Company, which together with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription medicines, are trading 7.86% and 46.51% above its 50-day and 200-day moving averages, respectively. Additionally, the stock has an RSI of 61.25. Get free access to your research report on GWPH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA